Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte M and Dextrose 5% is an intravenous solution that provides electrolytes and calories. Dextrose is a monosaccharide that serves as a source of calories and water for cellular metabolism. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain fluid and electrolyte balance, and acetate and gluconate act as bicarbonate precursors to correct acidosis.
ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.
Source of water, electrolytes, and calories for parenteral nutrition,Maintenance of fluid and electrolyte balance,Correction of metabolic acidosis (via acetate/gluconate)
Maintenance of fluid and electrolyte balance in patients unable to take oral intake,Correction of metabolic acidosis when bicarbonate is contraindicated or not available,Replacement of electrolytes in hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia
Intravenous infusion; adult dose determined by fluid and electrolyte needs; typical maintenance: 100-200 m L/hour (2-3 L/day) for normovolemic patients; adjust based on serum electrolytes, glucose, and clinical status.
Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.
Dextrose: <15 minutes (rapidly cleared from plasma); Electrolytes: No true half-life, as they are distributed and excreted according to homeostatic mechanisms.
Not applicable as a single agent; components have variable half-lives (e.g., sodium and chloride distribute rapidly with an elimination half-life of 2-4 hours depending on renal function). In renal impairment, half-life may be prolonged.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, providing energy. Acetate and gluconate are metabolized primarily in the liver and skeletal muscle to bicarbonate. Electrolytes are not metabolized.
Acetate and gluconate are metabolized in the liver via the tricarboxylic acid cycle to bicarbonate; electrolytes are distributed in body fluids and excreted renally.
Renal: 90% (as water and electrolytes); Dextrose is metabolized to CO2 and water, with negligible renal excretion of unchanged drug.
Renal: >95% of administered electrolytes and water are excreted unchanged by the kidneys, primarily as urine. Biliary/fecal: <5% eliminated via feces, mainly unabsorbed components.
Minimal (<5%) for electrolytes and dextrose; not significantly bound to plasma proteins.
Minimal to none: electrolytes like sodium, potassium, chloride, and bicarbonate are not protein-bound (<1%). Magnesium and calcium may have 30-50% binding to albumin, but overall negligible in solution.
Electrolytes: Vd of sodium ~0.6 L/kg (total body water); Dextrose: Vd ~0.2-0.3 L/kg (extracellular fluid); overall Vd approximates 0.6 L/kg.
Distributes primarily into extracellular fluid (ECF) with Vd approximately 0.2 L/kg for sodium and chloride; calcium and magnesium distribute into a larger volume (0.5-0.6 L/kg) due to intracellular uptake.
Not applicable; drug is only administered intravenously (IV), so bioavailability is 100%.
Intravenous: 100% (complete systemic availability). Not administered orally or by other routes for systemic effect.
Contraindicated in severe renal impairment (e GFR < 30 m L/min/1.73 m²) due to risk of potassium and magnesium accumulation; for e GFR 30-59 m L/min/1.73 m², reduce infusion rate by 50% and monitor electrolytes; no adjustment for e GFR ≥ 60 m L/min/1.73 m².
Contraindicated in patients with severe renal impairment (GFR < 30 m L/min) due to risk of hyperkalemia. For GFR 30-50 m L/min, reduce infusion rate by 50% and monitor serum potassium closely. No adjustment needed for GFR > 50 m L/min.
Child-Pugh Class A or B: no adjustment needed; Child-Pugh Class C: monitor serum magnesium and potassium closely due to reduced clearance; consider reduced infusion rate (e.g., 75% of normal) and frequent electrolyte monitoring.
Child-Pugh Class A: no adjustment. Class B: reduce infusion rate by 25% and monitor serum potassium. Class C: use with caution; consider alternative solutions due to risk of electrolyte imbalance.
Intravenous infusion; dose based on weight: infants: 100-150 m L/kg/day; children: 100-200 m L/kg/day; adjust for ongoing losses and serum glucose; not recommended for neonates due to risk of hyperkalemia; maximum infusion rate 2-5 m L/kg/hour depending on age and clinical status.
Weight-based dosing: 20-30 m L/kg as a single intravenous infusion, administered at a rate not exceeding 5 m L/kg/hour. Maximum total volume: 1000 m L. Adjust based on clinical status and serum electrolytes.
Elderly patients: use lower initial rates (e.g., 50-100 m L/hour) with careful monitoring of fluid overload, serum electrolytes, and glucose tolerance; due to age-related renal decline, consider dose reduction if e GFR < 60 m L/min/1.73 m²; avoid in patients with heart failure or significant renal impairment.
Elderly patients may require reduced infusion rates (2-5 m L/min) due to decreased renal function and higher risk of fluid overload. Monitor serum potassium and renal function closely.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to any component.
None
Use with caution in patients with heart failure, renal impairment, or conditions predisposing to fluid overload.,Monitor serum glucose, electrolytes, and fluid status regularly.,Avoid rapid infusion to prevent hyperglycemia and osmotic diuresis.,Do not administer simultaneously with blood through the same infusion set (risk of hemolysis) unless using a Y-type connector with proper flushing.
Monitor serum electrolytes, fluid balance, and renal function regularly. Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hypervolemia. Avoid rapid infusion; extravasation may cause tissue damage. Contains aluminum, which may accumulate in renal impairment.
Severe hyperglycemia (e.g., diabetic ketoacidosis),Hyperkalemia,Severe renal impairment with oliguria or anuria,Hypersensitivity to any component
Hyperkalemia, hypernatremia, hypercalcemia, hypermagnesemia, severe metabolic alkalosis, severe renal failure with oliguria or anuria, and patients with a known hypersensitivity to any component.
No specific food interactions. Dietary potassium/magnesium intake should be monitored in patients receiving this solution to avoid electrolyte imbalance. Patients with diabetes should coordinate dextrose infusion with insulin and meal timing.
No direct food interactions; however, patients should avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia is a concern. Monitor dietary sodium and fluid intake as per clinical status.
No evidence of teratogenicity. Plasma-Lyte M and Dextrose 5% is an isotonic crystalloid solution; dextrose and electrolytes are normal physiological constituents. Fetal risk is negligible as the solution is designed to replace fluids and electrolytes. No teratogenic effects reported in animal studies or human data. Trimester-independent low risk, but use only if clearly needed.
ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid administration may cause maternal fluid and electrolyte disturbances that can indirectly affect the fetus. Use with caution in the setting of impaired uteroplacental perfusion.
Compatible with breastfeeding. Components (dextrose, electrolytes) are endogenous and present in breast milk. No known M/P ratio available as the solution is composed of substances normally present in milk. Excretion is not clinically relevant; no adverse effects expected.
ISOLYTE E is compatible with breastfeeding. Electrolytes are normally present in breast milk; exogenous administration does not significantly alter infant exposure. M/P ratio not applicable as drug is not a xenobiotic.
No specific dose adjustments required. Pregnancy induces increased plasma volume (40-50%) and glomerular filtration rate (50-85%), but crystalloid solutions like Plasma-Lyte M and Dextrose 5% are dosed based on clinical need (fluid replacement, maintenance). Monitor for hyperglycemia due to dextrose; consider lower infusion rates in gestational diabetes or preeclampsia-related fluid sensitivity.
No dose adjustment is required for pregnancy. However, pregnant patients may have increased plasma volume and altered renal function; infusion rates should be individualized based on clinical status and serum electrolyte monitoring. Rapid correction of electrolyte imbalances should be avoided to prevent fetal osmotic shifts.
PLASMA-LYTE M AND DEXTROSE 5% is a balanced isotonic crystalloid containing multiple electrolytes (Na 40, K 13, Mg 3, Cl 40, acetate 16, gluconate 20 m Eq/L) with 5% dextrose. It is used for maintenance fluid therapy, particularly in pediatric or geriatric patients, or when mild potassium/magnesium supplementation is needed. The dextrose provides ~170 kcal/L and helps prevent ketosis. Avoid in patients with hyperkalemia, hypermagnesemia, or anuria. Acetate and gluconate serve as bicarbonate precursors (acetate is rapidly metabolized; gluconate slower). Monitor serum glucose in diabetics or stress states. Compatible with most IV medications; check specific compatibility.
ISOLYTE E is a balanced electrolyte solution with 5% dextrose, used for maintenance fluid therapy. Monitor serum potassium closely in renal impairment; contains 20 m Eq/L potassium. Caution in patients with hyperkalemia, renal failure, or metabolic alkalosis. Do not administer simultaneously with blood products due to risk of hemolysis. Observe for signs of fluid overload in patients with heart failure.
This intravenous solution contains sugar (dextrose) and electrolytes to maintain fluid balance and provide calories.,Tell your healthcare provider if you have diabetes, kidney problems, or heart disease.,Report any signs of fluid overload: swelling, shortness of breath, or rapid weight gain.,This solution may be given with other medications; inform your nurse of all medications you are taking.,You may experience a cold sensation at the IV site; this is usually temporary.
This solution is used to replace fluids and electrolytes and provide calories. Tell your doctor if you have kidney problems, heart disease, or are on a low-potassium diet. Report any swelling, shortness of breath, or irregular heartbeat. Do not take over-the-counter potassium supplements without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte M and Dextrose 5% is an intravenous solution that provides electrolytes and calories. Dextrose is a monosaccharide that serves as a source of calories and water for cellular metabolism. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain fluid and electrolyte balance, and acetate and gluconate act as bicarbonate precursors to correct acidosis.. ISOLYTE E IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; adult dose determined by fluid and electrolyte needs; typical maintenance: 100-200 m L/hour (2-3 L/day) for normovolemic patients; adjust based on serum electrolytes, glucose, and clinical status.. The standard adult dose of ISOLYTE E IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity. Plasma-Lyte M and Dextrose 5% is an isotonic crystalloid solution; dextrose and electrolytes are normal physiological constituents. Fetal risk is neg. ISOLYTE E IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.